The present disclosure belongs to the field of tumor diagnosis, and specifically relates to a biomarker panel, a microfluidic device and a detection kit for capturing circulating tumor cells. The biomarker panel includes a first biomarker and a second biomarker; wherein: the first biomarker is EPCAM; the second biomarker is one or a combination of two or more of CD9, CD41, THBS1, RGS18, and RGS10; the circulating tumor cells are pancreatic cancer circulating tumor cells and/or breast cancer circulating tumor cells. In the present disclosure, by using antibodies against novel surface biomarkers of pancreatic cancer or breast cancer circulating tumor cells (CTCs), the enrichment and detection rate of CTCs in the blood of patients are significantly improved, and the possibility of missed detection is effectively reduced; meanwhile, the capture and enrichment efficiency of CTCs are enhanced, thus providing strong support for dynamic tumor monitoring, prognostic evaluation and personalized precise treatment of cancer patients, and offering broad market value and application prospects.

Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (v3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (v3) pathway, wherein the sensitivity is determined by methods as provided herein.